Company / Cash & Equivalents
4D Molecular Therapeutics, Inc. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$60.2M
FY2025
5-year range
$52.4M / $249.1M
FY2021-FY2025
Trend
-59.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $249M to $60M over the past 2 years.
Based on SEC 10-K filings.
$60M in FY2025 with a 5-year CAGR of -26.3%.
Declined from $249M to $60M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +4.8%
- 5-Year CAGR
- -26.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -26.3%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 59.7% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
- Lowest cash & equivalents in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $60.2M | -59.7% |
| FY2024 | $149.3M | -40.1% |
| FY2023 | $249.1M | +375.8% |
| FY2022 | $52.4M | -65.8% |
| FY2021 | $153.0M | -44.7% |
| FY2020 | $276.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026